Crossmark

Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study

Crossref DOI link: https://doi.org/10.1016/j.gastrohep.2021.05.015

Published Print: 2022-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Turnes, Juan

Rincón, Diego

Calleja, José L.

Delgado, Manuel B.

Rosales, José M. http://orcid.org/0000-0001-6751-6720
Andrade, Raúl J.

Manzano, María L.

Salmerón, Francisco J.

López, María A.

Calvo, Marta

Gómez, Judith

Molina, Esther

Frias, Yza Nubia

Gálvez-Fernández, Roque Miguel

Vallejo-Senra, Nicolau

París, Sara http://orcid.org/0000-0001-5653-3779
Santos de Lamadrid, Regina

Olveira, Antonio
Funding

Funding for this research was provided by:

Gilead Sciences

Meso Scale Diagnostics
License Information

Text and Data Mining valid from 2022-05-01

stm-asf valid from 2022-05-01

stm-asf valid from 2022-05-01

stm-asf valid from 2022-05-01

stm-asf valid from 2022-05-01

stm-asf valid from 2022-05-01
More Information

This article is maintained by: Elsevier

Article Title: Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study

Journal Title: Gastroenterología y Hepatología

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.gastrohep.2021.05.015

Content Type: article

Copyright: © 2021 Elsevier España, S.L.U. All rights reserved.

Document is current

Any future updates will be listed below